Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 24;10:873. doi: 10.3389/fimmu.2019.00873

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Millán, Ruiz, Orts, Ferré, Crespo, Santana, Fortuna, Quintairos, Navasa and Brunet.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Evolution of miR-155-5p, miR-122-5p, and miR-181a-5p expression in patients experiencing the recurrence of HCV⁺. Differences between patients free of any clinical event (gray boxes) and HCV⁺ patients (white boxes) with respect to (A) miR-155-5p; (B) miR-181a-5p and (C) miR-122-5p expression during 1 year post-transplantation. Five patients developed HCV recurrence after transplantation (n = 3 HCV RNA⁺ patients until the 3rd month post-transplantation, with exitus occurring in one of them; one patient, until the 2nd month; and one patient, until the 6th month). Graph (D) shows the individual evolution in miR-122-5p expression in 3 patients with HCV⁺. The dashed horizontal line indicates the post-transplantation cut-off value for the risk of TCMAR (4.356) with respect to miR-122-5p expression.